Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results

被引：0
|
作者：
Pettengell, Ruth [1 ]
Zinzani, Pier Luigi [2 ]
Narayanan, Geetha [3 ]
de Mendoza, Fernando Hurtado [4 ]
Digumarti, Raghunadharao [5 ]
Gomez, Henry [6 ]
Coiffier, Bertrand [7 ]
Schiller, Gary [8 ]
Rizzieri, David A. [9 ]
Cernohous, Paul [10 ]
Wang, Lixia [10 ]
Singer, Jack [10 ]
机构：
[1] St Georges Univ London, London, England
[2] Ist Ematol, Policlin S Orsola, Bologna, Italy
[3] Reg Canc Ctr, Div Med Oncol, Thiruvananthapuram, Kerala, India
[4] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[5] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[6] Hosp Edgardo Rebagliati Martins, Lima, Peru
[7] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[8] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA
[9] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC USA
[10] Cell Therapeut Inc, Seattle, WA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1168 / 1169
页数：2
相关论文
共 47 条
  • [1] Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma
    Pettengell, R.
    Narayanan, G.
    Mendoza, F. H.
    Digumarti, R.
    Gomez, H.
    Cernohous, P.
    Gorbatchevsky, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
    Pettengell, Ruth
    Coiffier, Bertrand
    Narayanan, Geetha
    Hurtado de Mendoza, Fernando
    Digumarti, Raghunadharao
    Gomez, Henry
    Zinzani, Pier Luigi
    Schiller, Gary
    Rizzieri, David
    Boland, Giles
    Cernohous, Paul
    Wang, Lixia
    Kuepfer, Christine
    Gorbatchevsky, Igor
    Singer, Jack W.
    LANCET ONCOLOGY, 2012, 13 (07): : 696 - 706
  • [3] EXTEND PIX301: A phase III randomized trial of pixantrone versus other chemotherapeutic agents as third-line monotherapy in patients with relapsed, aggressive non-Hodgkin's lymphoma
    Engert, Andreas
    Herbrecht, Rauol
    Santoro, Armando
    Zinzani, Pier Luigi
    Gorbatchevsky, Igor
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02): : 152 - 155
  • [4] Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial (vol 13, pg 696, 2012)
    Pettengell, R.
    Coiffier, B.
    Narayanan, G.
    LANCET ONCOLOGY, 2012, 13 (07): : E285 - E285
  • [5] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    Witzig, T. E.
    Vose, J. M.
    Zinzani, P. L.
    Reeder, C. B.
    Buckstein, R.
    Polikoff, J. A.
    Bouabdallah, R.
    Haioun, C.
    Tilly, H.
    Guo, P.
    Pietronigro, D.
    Ervin-Haynes, A. L.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
  • [6] Results of. a phase II study of pixantrone in combination with cyclophospamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Kutz, Klaus
    Stromatt, Scott
    Engert, Andreas
    BLOOD, 2006, 108 (11) : 160A - 160A
  • [7] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab
    Davis, TA
    White, CA
    Grillo-López, AJ
    Velásquez, WS
    Link, B
    Maloney, DG
    Dillman, RO
    Williams, ME
    Mohrbacher, A
    Weaver, R
    Dowden, S
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1851 - 1857
  • [8] A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
    Stopeck, Alison T.
    Unger, Joseph M.
    Rimsza, Lisa M.
    Bellamy, William T.
    Iannone, Maria
    Persky, Daniel O.
    Leblanc, Michael
    Fisher, Richard I.
    Miller, Thomas P.
    LEUKEMIA & LYMPHOMA, 2009, 50 (05) : 728 - 735
  • [9] Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Santoro, A.
    Voglova, J.
    Gabrail, N.
    Ciuleanu, T.
    Liberati, M.
    Hancock, B. W.
    Stromatt, S.
    Caballero, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 441S - 441S
  • [10] Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma
    Georgiev, P. G.
    Belada, D.
    Dakhil, S.
    Inhorn, L. F.
    Andorsky, D.
    Liberati, A. M.
    Beck, J. T.
    Quick, D.
    Patti, C.
    Sivcheva, L.
    Zaucha, J. M.
    Pettengell, R.
    Devries, T.
    Dean, J. P.
    Pavlyuk, M.
    Failloux, N.
    Huebel, K.
    ANNALS OF ONCOLOGY, 2016, 27
12345